In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations

被引：52

作者：

Shelburne, SA

Musher, DM

Hulten, K

Ceasar, H

Lu, MY

Bhaila, I

Hamill, RJ

机构：

[1] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA

[2] Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA

[3] Baylor Coll Med, Infect Dis Sect, Dept Pediat, Houston, TX 77030 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 10期

关键词：

D O I：

10.1128/AAC.48.10.4016-4019.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.

引用

收藏

页码：4016 / 4019

页数：4

相关论文

共 32 条

[21] METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS - A CONSENSUS REVIEW OF THE MICROBIOLOGY, PATHOGENESIS, AND EPIDEMIOLOGY WITH IMPLICATIONS FOR PREVENTION AND MANAGEMENT [J].

MULLIGAN, ME ;

MURRAYLEISURE, KA ;

RIBNER, BS ;

STANDIFORD, HC ;

JOHN, JF ;

KORVICK, JA ;

KAUFFMAN, CA ;

YU, VL .

AMERICAN JOURNAL OF MEDICINE, 1993, 94 (03) :313-328

[22] Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection [J].

Naimi, TS ;

LeDell, KH ;

Como-Sabetti, K ;

Borchardt, SM ;

Boxrud, DJ ;

Etienne, J ;

Johnson, SK ;

Vandenesch, F ;

Fridkin, S ;

O'Boyle, C ;

Danila, RN ;

Lynfield, R .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (22) :2976-2984

[23] Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998 [J].

Naimi, TS ;

LeDell, KH ;

Boxrud, DJ ;

Groom, AV ;

Steward, CD ;

Johnson, SK ;

Besser, JM ;

O'Boyle, C ;

Danila, RN ;

Cheek, JE ;

Osterholm, MT ;

Moore, KA ;

Smith, KE .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) :990-996

[24] TREATMENT OF EXPERIMENTAL CHRONIC OSTEOMYELITIS DUE TO STAPHYLOCOCCUS-AUREUS WITH VANCOMYCIN AND RIFAMPIN [J].

NORDEN, CW ;

SHAFFER, M .

JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (02) :352-357

[25] Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community [J].

Okuma, K ;

Iwakawa, K ;

Turnidge, JD ;

Grubb, WB ;

Bell, JM ;

O'Brien, FG ;

Coombs, GW ;

Pearman, JW ;

Tenover, FC ;

Kapi, M ;

Tiensasitorn, C ;

Ito, T ;

Hiramatsu, K .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (11) :4289-4294

[26] Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots [J].

Palmer, SM ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :701-705

[27] VANCOMYCIN FOR STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN INTRAVENOUS-DRUG-USERS [J].

SMALL, PM ;

CHAMBERS, HF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1227-1231

[28]

Vandenesch F, 2003, EMERG INFECT DIS, V9, P978

[29]

VANDERAUWERA P, 1983, REV INFECT DIS, V5, pS515

[30]

VANDERAUWERA P, 1987, J ANTIMICROB CHEMOTH, V19, P313

← 1 2 3 4 →